Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
暂无分享,去创建一个
A. Gasbarrini | M. Zoli | G. Svegliati-Baroni | F. Marra | E. Giannini | F. Farinati | M. Di Marco | E. Caturelli | R. Sacco | G. Cabibbo | A. Mega | F. Foschi | A. Masotto | G. Nardone | F. Trevisani | A. Olivani | F. Morisco | M. Persico | A. Craxì | S. Petta | A. Colecchia | S. Attardo | F. Ciccarese | L. Bucci | F. Borzio | R. Virdone | L. Benvegnu' | G. Negrini | C. Cammà | M. Barbara | G. Rapaccini | Giulia Negrini
[1] P. Schirmacher,et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.
[2] M. Colombo,et al. A meta‐analysis of single HCV‐untreated arm of studies evaluating outcomes after curative treatments of HCV‐related hepatocellular carcinoma , 2017, Liver international : official journal of the International Association for the Study of the Liver.
[3] A. Gasbarrini,et al. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma , 2017, Liver international : official journal of the International Association for the Study of the Liver.
[4] W. Kim,et al. Reduction in liver transplant wait‐listing in the era of direct‐acting antiviral therapy , 2017, Hepatology.
[5] A. Gasbarrini,et al. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon , 2017, Alimentary pharmacology & therapeutics.
[6] M. Colombo,et al. Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. , 2016, Journal of hepatology.
[7] J. Vauthey,et al. Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment. , 2016, Journal of hepatology.
[8] G. Cabibbo,et al. Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing. , 2016, Journal of hepatology.
[9] L. Bolondi,et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. , 2016, Journal of hepatology.
[10] A. Walker,et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. , 2016, Journal of hepatology.
[11] J. Bruix,et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. , 2016, Journal of hepatology.
[12] R. Facchetti,et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. , 2016, Journal of hepatology.
[13] G. Cabibbo,et al. Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension. , 2016, Gastroenterology.
[14] S. Pol. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. , 2016, Journal of hepatology.
[15] J. Bruix,et al. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. , 2016, Gastroenterology.
[16] R. Sacco,et al. The calm before the storm: a report from the International Liver Cancer Association Congress 2015--part 1. , 2016, Future oncology.
[17] M. Makuuchi,et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. , 2015, The Lancet. Oncology.
[18] T. Greten,et al. The yin and yang of evasion and immune activation in HCC. , 2015, Journal of hepatology.
[19] Korea,et al. 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma , 2015, Gut and liver.
[20] V. Mazzaferro,et al. Early Hepatocellular Carcinoma on the Procrustean Bed of Ablation, Resection, and Transplantation , 2014, Seminars in Liver Disease.
[21] M. Iavarone,et al. Role of antiviral treatment for HCC prevention. , 2014, Best practice & research. Clinical gastroenterology.
[22] R. Bruno,et al. Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. , 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[23] Shou-Dong Lee,et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. , 2009, Journal of hepatology.
[24] A. Sanyal,et al. Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis , 2007, The American Journal of Gastroenterology.
[25] A. Sanyal,et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. , 2007, The American journal of gastroenterology.
[26] M. Latteri,et al. Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. , 2005, Journal of hepatology.
[27] S. Kawasaki,et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. , 2003, Journal of hepatology.
[28] P. Kamath,et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts , 2000, Hepatology.
[29] H. Moriwaki,et al. Prevention of Second Primary Tumors by an Acyclic Retinoid, Polyprenoic Acid, in Patients with Hepatocellular Carcinoma , 1998, Digestion.
[30] V. Mazzaferro,et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.
[31] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[32] R. Pugh,et al. Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.
[33] M. Ziol,et al. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. , 2017, Gastroenterology.
[34] J. Bruix,et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution , 2016 .
[35] A. Dreher. Modeling Survival Data Extending The Cox Model , 2016 .
[36] Riccardo Lencioni,et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, Journal of hepatology.